Supernus Pharmaceuticals Operating Income 2011-2024 | SUPN
Supernus Pharmaceuticals operating income from 2011 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Supernus Pharmaceuticals Annual Operating Income
(Millions of US $) |
| 2023 |
$-5 |
| 2022 |
$46 |
| 2021 |
$86 |
| 2020 |
$174 |
| 2019 |
$149 |
| 2018 |
$144 |
| 2017 |
$100 |
| 2016 |
$54 |
| 2015 |
$21 |
| 2014 |
$-5 |
| 2013 |
$-62 |
| 2012 |
$-42 |
| 2011 |
$-38 |
| 2010 |
$-40 |
Supernus Pharmaceuticals Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$41 |
| 2024-06-30 |
$23 |
| 2024-03-31 |
$-3 |
| 2023-12-31 |
$-1 |
| 2023-09-30 |
$8 |
| 2023-06-30 |
$-18 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$34 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$11 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$6 |
| 2021-09-30 |
$33 |
| 2021-06-30 |
$34 |
| 2021-03-31 |
$13 |
| 2020-12-31 |
$43 |
| 2020-09-30 |
$56 |
| 2020-06-30 |
$46 |
| 2020-03-31 |
$29 |
| 2019-12-31 |
$41 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
$43 |
| 2019-03-31 |
$25 |
| 2018-12-31 |
$40 |
| 2018-09-30 |
$37 |
| 2018-06-30 |
$36 |
| 2018-03-31 |
$31 |
| 2017-12-31 |
$34 |
| 2017-09-30 |
$22 |
| 2017-06-30 |
$26 |
| 2017-03-31 |
$17 |
| 2016-12-31 |
$16 |
| 2016-09-30 |
$20 |
| 2016-06-30 |
$12 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$4 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$5 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$4 |
| 2014-03-31 |
$-13 |
| 2013-12-31 |
$-11 |
| 2013-09-30 |
$-17 |
| 2013-06-30 |
$-15 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-13 |
| 2012-09-30 |
$-12 |
| 2012-06-30 |
$-9 |
| 2012-03-31 |
$-8 |
| 2011-12-31 |
$-10 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-8 |
| 2011-03-31 |
$-9 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.000B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
